Phase 2 N=31 Safety Study of Dantrolene in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Cerebral Vasospasm
Primary: Hyponatremia — 7; 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=18 Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Castrate-resistant Prostate Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths — 11; 7; 7; 4 participants
Phase 3 N=38 Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation
Inflammation · Macrophage Infiltration · Cardiovascular Disease
Primary: Inflammatory Biomarker 1: Plasma hsCRP Concentration — 3.4; 5.4; 2.9; 7.4 mg/L — p=0.006
N/A N=40 Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute
COPD
Primary: Safety and Efficacy of the Lung Flute Versus the Acapella for the Treatment of COPD in Adults. Twenty-four (24) Hour Dry Sputum Weight — 11.9; 14.5; 14.4; 14.3 g
Phase 4 N=17 Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)
Flushing
Primary: Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin — 9.9; 9.4; 7.7; 8.9 Fold change over baseline — p=0.5
Phase 4 N=56 Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery
Pain, Postoperative
Primary: Postoperative Pain Assessed on Standard VAS Scale — 0.48; 1.12 units on a scale
Phase 3 N=351 A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) — 52.1; 20.1 weeks — p=<0.001
Phase 2 N=41 Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group — 41.8; 88.9 mEq/min — p=0.26
Phase 2 N=25 Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults
Cough
Primary: Lung Volume Initiation — 23.3 % Vital Capacity, relative to EEL
Phase 2 N=200 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Myositis · Dermatomyositis · Polymyositis
Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74
Phase 2 N=147 Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation
Colonic Neoplasms
Primary: Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy — 18.69; 20.1 Score
N/A N=256 The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
Coronary Heart Disease
Primary: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration — 48.08; 66.79 MIF Concentration,ug/L
Phase 2 N=71 Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants
Phase 2 N=1,507 Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants
Meningococcal Meningitis · Meningococcal Infections
Primary: Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination — 5; 2; 4; 4 Percentages of Subjects
Phase 3 N=2,249 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Meningococcal Disease
Primary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination — 81; 82; 100; 100 Percentages of…